Merck Revenue Soars, Setting High Bar For Future Growth

Business Development A Priority For New Spending

With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028. 

Businessman plans business growth with increases through 2022
Merck expects double-digit growth in full-year 2022 revenue as well • Source: Shutterstock

Merck & Co., Inc. delivered double-digit revenue growth during the third quarter, largely driven by increasing use of its market-leading PD-1 inhibitor Keytruda (pembrolizumab) in new indications, including earlier lines of cancer treatment. The success of its top seller brings both investor enthusiasm about current gains and concerns about keeping the growth momentum going into the future, especially as the prospect of Keytruda biosimilars in 2028 edges closer.

Merck’s Q3 earnings report on 27 October showed how dependent the company currently is on the immuno-oncology asset, which generated...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.